drugset / Trial / NCT04023253
Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin
RandomizedParallel-groupOpen-labelTreatment
Summary
To assess the impact of mirabegron versus solifenacin on psychological distress, sexual function, bladder wall thickness and bladder blood flow.
Timeline
- Start
- 2019-08-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirabegron | Other / unclassified | 25 mg | — |
| Subject | Solifenacin | Small molecule | 5 mg | — |